Searchable abstracts of presentations at key conferences in obesity

ob0003p1 | All items | OU2021

Development of severe gastroparesis and gastric food bezoar following administration of glucagon-like peptide 1-receptor agonist (GLP1-RA) therapy

Preda Veronica , Khoo Su Yee , Lord Reginald

With the global increase in obesity and diabetes, the use of weight negative therapy, such as the glucagon-like peptide -1 receptor agonists (GLP-1 RA) are increasing. The most common side effects with the GLP-1RA are gastrointestinal symptoms, mainly nausea. Other common adverse effects include headache, injection site reactions, and are usually minor and do not result in cessation of therapy. GLP-1RA are also associated with slowed gastric emptying, by virtue of their mode o...